Evidence map›Paper›PMID 41617275›Full record

ArticleCarbohydrate polymers2026

Nitric oxide-releasing dextran surface with enhanced albumin affinity mitigates infection and foreign body reaction.

Yi Wu, Aasma Sapkota, Sarah N Wilson, Stephen G Thompson, Mark R Garren, Hitesh Handa, Elizabeth J Brisbois

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Carbohydrate polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi WuSchool of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA, 30602, United States.
Aasma SapkotaSchool of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA, 30602, United States.
Sarah N WilsonSchool of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA, 30602, United States.
Stephen G ThompsonSchool of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA, 30602, United States.
Mark R GarrenSchool of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA, 30602, United States.
Hitesh HandaSchool of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA, 30602, United States; Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, 30602, United States. Electronic address: hhanda@uga.edu.
Elizabeth J BrisboisSchool of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA, 30602, United States. Electronic address: ejbrisbois@uga.edu.

Funding

Engineering nitric oxide releasing polymer with immobilized thrombin inhibitor for blood contacting applicationsR01HL134899 · NHLBI · UNIVERSITY OF GEORGIA · PI HANDA, HITESH · 2017 to 2025
$3.0M
Bioinspired antifouling and thromboresistant polymers for blood-contacting interfacesR01HL151473 · NHLBI · UNIVERSITY OF GEORGIA · PI BRISBOIS, ELIZABETH JOY · 2020 to 2023
$1.4M
NHLBI NIH HHS R01 HL134899NHLBI NIH HHS R01 HL151473
6 · The paper itself

Abstract

Medical device surfaces often lack the blood compatibility and features of native endothelium, leading to issues from blood-material interactions and infection. Procoagulant plasma proteins rapidly adsorb to these surfaces, triggering the coagulation cascade. Concurrently, bacteria may adhere to these foreign surfaces, developing biofilms. To address these issues, we developed a hybrid nitric oxide (NO)-releasing material by integrating the NO donor S-nitroso-N-acetylpenicillamine into polydimethylsiloxane (PDMS), followed by its surface functionalization with blue dextran (NOBD). Blue dextran preferentially binds albumin, reducing adsorption of other plasma proteins as well as its selective displacement, thereby minimizing coagulation cascade activation. Simultaneously, NO release inhibits platelet activation and enables antimicrobial protection. Surface characterization confirmed the stability of the NOBD technology over 24 h under physiological conditions. In kinetics studies, NO release rates remained within vascular levels (0.5-4.0 × 10

Indexed as

AlbuminsDextransForeign BodiesNitric OxideAnimalsAnti-Bacterial AgentsBacterial AdhesionBlood PlateletsCell LineDimethylpolysiloxanesErythrocytesEscherichia coliFibrinogenFibroblastsMicePlatelet AdhesivenessAlbuminsAnti-Bacterial AgentsbaysilonDextransDimethylpolysiloxanesFibrinogenNitric OxideS-Nitroso-N-AcetylpenicillamineAntifoulingDextranHemocompatibleInfectionNitric oxideS-nitroso-N-acetylpenicillamine

Identifiers

PMID41617275
PMCPMC12866958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.